Displaying drugs 14401 - 14425 of 15057 in total
ECT204
ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.
Investigational
Sapablursen
Sapablursen is a synthetic 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a tri-antennary cluster of N-acetyl galactosamine (GalNAc3) sugars targeting transmembrane protease, serine 6 messenger ribonucleic acid
Investigational
CTX130
CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.
Investigational
Allogeneic natural killer cells
Investigational
AVR-RD-05
AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced ex vivo with a lentiviral vector encoding the human iduronate-2-sulfatase (IDS) enzyme. It is under investigation for the treatment of Hunter Syndrome (Mucopolysaccharidosis Type II, MPSII).
Investigational
MaaT013
MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.
Investigational
Allogeneic human pancreatic islets of Langerhans
Investigational
ssCART-19 cells
ssCART-19 cells consist of autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6).
Investigational
Autologous CD4+CD25hiFoxP3+regulatory T cells
Investigational
Avoplacel
Avoplacel (PLX-R18) is an allogeneic cell therapy under investigation for the treatment of acute radiation syndrome.
Investigational
Rugonersen
Rugonersen is a locked nucleic acid antisense oligonucleotide under investigation for the treatment of Angelman Syndrome.
Investigational
Ulefnersen
Investigational
RC88
RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).
Investigational
HLX-58
HLX-58 is an investigational monoclonal antibody targeted against claudin 18.2.
Investigational
SHR-A1904
SHR-A1904 is under investigation in clinical trial NCT04877717 (A Study of SHR-A1904 in Patients With Advanced Solid Cancer).
Investigational
rAAV1-CB-hAAT
rAAV1-CB-hAAT is a recombinant adeno-associated virus alpha 1-antitrypsin vector.
Investigational
BVX-001
BVX001 is a a novel, first-in-class CD33/CD7-directed antibody-drug conjugate.
Investigational
MS1901
Investigational
Zamtocabtagene autoleucel
Investigational
Lusvertikimab
Investigational
GXC-301
Investigational
Displaying drugs 14401 - 14425 of 15057 in total